Evidence map›Paper›PMID 39334289›Full record

ArticleBMC medicine2024

Estimating pneumococcal carriage dynamics in adults living with HIV in a mature infant pneumococcal conjugate vaccine programme in Malawi, a modelling study.

Joseph Phiri, Lusako Sibale, Lukerensia Mlongoti, Ndaona Mitole, Alice Kusakala, Mercy Khwiya, Thokozani Kayembe, Edwin Lisimba, Prosperina Kapwata, Ken Malisita and 4 more

Abstract read
In one paragraph

Article in BMC medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Joseph Phiri *Malawi-Liverpool-Wellcome Programme, Blantyre, Malawi.
Lusako Sibale *Malawi-Liverpool-Wellcome Programme, Blantyre, Malawi.
Lukerensia MlongotiMalawi-Liverpool-Wellcome Programme, Blantyre, Malawi.
Ndaona MitoleMalawi-Liverpool-Wellcome Programme, Blantyre, Malawi.
Alice KusakalaMalawi-Liverpool-Wellcome Programme, Blantyre, Malawi.
Mercy KhwiyaMalawi-Liverpool-Wellcome Programme, Blantyre, Malawi.
Thokozani KayembeMalawi-Liverpool-Wellcome Programme, Blantyre, Malawi.
Edwin LisimbaMalawi-Liverpool-Wellcome Programme, Blantyre, Malawi.
Prosperina KapwataLighthouse-Queens Elizabeth Hospital and Gateway Health Centre, Blantyre, Malawi.
Ken MalisitaLighthouse-Queens Elizabeth Hospital and Gateway Health Centre, Blantyre, Malawi.
Chrispin ChaguzaYale Institute for Global Health, Yale University, New Haven, CT, USA.
Daniela M FerreiraDepartment of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.
Deus Thindwa *Malawi-Liverpool-Wellcome Programme, Blantyre, Malawi. deus.thindwa@gmail.com.
Kondwani Jambo *Malawi-Liverpool-Wellcome Programme, Blantyre, Malawi. kondwani.jambo@lstmed.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAdults living with human immunodeficiency virus (ALWHIV) receiving antiretroviral therapy (ART) exhibit higher pneumococcal carriage prevalence than adults without HIV (HIV-). To assess factors influencing high pneumococcal carriage in ALWHIV, we estimated pneumococcal carriage acquisition and clearance rates in a high transmission and disease-burdened setting at least 10 years after introducing infant PCV13 in routine immunisation.

methodsWe collected longitudinal nasopharyngeal swabs from individuals aged 18-45 in Blantyre, Malawi. The study group included both HIV- individuals and those living with HIV, categorised based on ART duration as either exceeding 1 year (ART > 1y) or less than 3 months (ART < 3 m). Samples were collected at baseline and then weekly for 16 visits. To detect pneumococcal carriage, we used classical culture microbiology, and to determine pneumococcal serotypes, we used latex agglutination. We modelled trajectories of serotype colonisation using multi-state Markov models to capture pneumococcal carriage dynamics, adjusting for age, sex, number of under 5 year old (< 5y) children, social economic status (SES), and seasonality.

resultsWe enrolled 195 adults, 65 adults in each of the study groups. 51.8% were females, 25.6% lived with more than one child under 5 years old, and 41.6% lived in low socioeconomic areas. The median age was 33 years (IQR 25-37 years). The baseline pneumococcal carriage prevalence of all serotypes was 31.3%, with non-PCV13 serotypes (NVT) at 26.2% and PCV13 serotypes (VT) at 5.1%. In a multivariate longitudinal analysis, pneumococcal carriage acquisition was higher in females than males (hazard ratio [HR], NVT [1.53]; VT [1.96]). It was also higher in low than high SES (NVT [1.38]; VT [2.06]), in adults living with 2 + than 1 child < 5y (VT [1.78]), and in ALWHIV on ART > 1y than HIV- adults (NVT [1.43]). Moreover, ALWHIV on ART > 1y cleared pneumococci slower than HIV- adults ([0.65]). Residual VT 19F and 3 were highly acquired, although NVT remained dominant.

conclusionsThe disproportionately high point prevalence of pneumococcal carriage in ALWHIV on ART > 1y is likely due to impaired nasopharyngeal clearance, which results in prolonged carriage. Our findings provide baseline estimates for comparing pneumococcal carriage dynamics after implementing new PCV strategies in ALWHIV.

Indexed as

Carrier StateHIV InfectionsNasopharynxPneumococcal InfectionsPneumococcal VaccinesStreptococcus pneumoniaeAdolescentAdultFemaleHumansInfantLongitudinal StudiesMalawiMaleMiddle AgedVaccines, Conjugate13-valent pneumococcal vaccinePneumococcal VaccinesVaccines, ConjugateHuman immunodeficiency virusMalawiModellingPneumococcal acquisitionPneumococcal durationSerotype

Identifiers

PMID39334289
PMCPMC11438070

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.